SUMMARY The mortality rate from myocardial infarction is disproportionately high in diabetic patients. One explanation for this may be that diabetic patients incur more extensive myocardial necrosis. This possibility was examined in a three part study. Firstly, peak serum aspartate aminotransferase concentrations of all diabetic and non-diabetic patients admitted with myocardial infarction over a 16 year period were compared retrospectively. Secondly, peak aspartate aminotransferase concentrations in a series of diabetic patients and controls matched by age and sex were examined retrospectively. Thirdly, creatine kinase MB release and electrocardiographic measures of infarct size were investigated prospectively in a case/control study. Although cardiac failure and death were more common in the diabetic groups, there were no significant differences in estimates of infarct size between diabetic and non-diabetic patients in any of the studies.
Diabetic patients are at increased risk of death from myocardial infarction.'2 Not only is there a higher incidence of infarction3 but the case fatality rate is about 15 to 2-0 times higher than it is in nondiabetic patients.45
In general, the major determinant of mortality once the patient has reached hospital is the degree of myocardial necrosis,67 and, therefore, one explanation of the diabetic death rate could be more extensive infarction. There are theoretical reasons why this might be so-diabetic patients may have more extensive coronary disease8; local tissue oxygenation may be disproportionately impaired by a combination of basement membrane thickening,9 decreased deformability of red cells,'0 increased viscosity," and hypercoagulability of blood'2; also a relative insufficiency of insulin'3 is likely to lead to impairment of glycolysis (the only source of high energy phosphate in ischaemia '4) and to an undue increase in non-esterified fatty acids which may further increase infarct size. i5
Therefore, in trying to unravel the cause of the high mortality from myocardial infarction in diabetic patients it is important to determine whether Requests for reprints to Dr D J Gwilt, General Hospital, Standing Way, Eaglestone, Milton Keynes MK6 5LD.
Accepted for publication 12 July 1985 infarct size is greater in these patients. We have evaluated infarct size in three separate surveys in an attempt to explore the possible causes of increased mortality from myocardial infarction in diabetic patients.
Patients and methods
We conducted three separate surveys. SURVEY 1967-83 All patients known before admission to be diabetic who were admitted to the coronary care unit between January 1967 In a second retrospective study all diabetic patients admitted from January 1979 to December 1983 with myocardial infarction were matched by age (± 5 years) and sex with the next appropriate nondiabetic patient who was admitted. For these patients peak aspartate aminotransferase, hospital course, and mortality were determined. To be sure that peak aspartate aminotransferase concentration had been measured we excluded patients admitted more than 48 hours after the onset of pain and those who died less than 24 hours after the onset of pain. SURVEY 198244 In a prospective study, all diabetic patients admitted from July 1982 to May 1984 suspected of having a myocardial infarction were paired with the next non-diabetic patient, matched by age (± 5 years), sex, and presence or absence of a previous history of myocardial infarction (irrespective of the number of infarcts). Patients were excluded if the onset of pain occurred more than 12 hours before admission to the coronary care unit. Blood was sampled on admission and every eight hours for 72 hours. All patients suspected of having an infarction were studied, but patients were later excluded if they did not meet the diagnostic criteria. Results from those who died within 72 hours (before the blood sampling was completed) were also excluded.
All patients had electrocardiographic monitoring for 24 hours with access to immediate write-out. We noted arrhythmias that were unlikely to be overlooked: complete heart block, ventricular fibrillation and atrial fibrillation. Left ventricular failure (diagnosed on the basis of the following-a third heart sound, widespread crepitations, or a chest x ray film showing pulmonary oedema) and cardiogenic shock (hypotension, poor perfusion, and low urine output) were also noted. Comparison of creatine kinase MB kinetics We analysed the release of creatine kinase MB in the diabetic and non-diabetic patients by comparing the disappearance coefficient and the time to peak creatine kinase MB in the two groups. In addition, the creatine kinase MB released was found for each patient at 6, 12, 18, and 24 hours by extrapolation of each curve and this was then expressed as a percentage of total creatine kinase MB released, these percentage values were averaged for the two groups so that accumulation curves for diabetic or nondiabetic patients could be compared.
Electrocardiographic analysis
To support the enzyme data we also used two simple electrocardiographic analyses of infarct size-QRS scoring"8 and the presence or absence of reciprocal ST depression.'9 For the QRS score the 12 lead electrocardiogram was recorded daily at a standard speed (25 mm/s) and sensitivity (1 mV/cm); the last available electrocardiogram up to and including the seventh day after infarction was analysed for this purpose. Patients with previous infarction, left ventricular hypertrophy, or conduction abnormalities were excluded from the QRS scoring study. Reciprocal depression was defined as ST depression of 1 mm or more in at least two leads remote from the infarct site and was scored as being present if seen on any electrocardiogram. Patients with electrocardiographic defects were also excluded from this study.
Study size From our initial study of aspartate aminotransferase and mortality in non-diabetic patients, it was evident that if the excess mortality in our hospital were solely the result of increased infarct size, then the diabetic population would be expected to have 50% more myocardial necrosis than the non-diabetic pa-468 tients. Using this figure, a power of 90%, the standard deviation of a pilot study on creatine kinase MB sizing of infarcts, and looking for significance at the 5% level we calculated that data from 25 matched pairs were needed to exclude a positive result20 (in the end we recruited 38 pairs).
STATISTICS
Groups were compared by Student's t tests and by x2 tests with the Yates's correction as appropriate.
Results RETROSPECTIVE STUDY 1967-83 From 1967 to 1983, the 456 diabetic patients admitted with myocardial infarction had a hospital mortality of 33.6%, in contrast to the 18-3% mortality (p<0001) in 1951 non-diabetic patients admitted over the four two year periods of the study. Serum aspartate aminotransferase levels and mortality data were available for 1516 (78%) of the non-diabetic patients and 328 (72%) of the diabetic group. The distributions of serum aspartate aminotransferase concentrations are almost identical in the two groups (Fig. 1 ). Mortality increased with peak aspartate aminotransferase in both groups (Fig. 2 ), but at any aspartate aminotransferase concentration mortality in the diabetics exceeded that in the non-diabetics (p<0001), suggesting that the excess mortality is not solely due to infarct size. CASE MATCHED STUDY 1979-83 Over the period of this study 167 diabetic patients were admitted with infarction; 50 died (30%). During the same period 228 (18-6%, p<0-001) of 1224 non-diabetic patients died. We studied 120 pairs of completion of enzyme sampling, 11 arrived 12 hours or more after the onset of pain, and three were excluded at the request of their own physician). Of the 41 remaining patients two could not be matched by the end of the study and one had a reinfarction 24 hours after admission. These patients were not included.
The 38 study patients (Table 2) had been diagnosed as diabetic a mean of 11 2 years ago; seven were being treated by diet, 20 with oral agents, and 11 with insulin; five had some degree of retinopathy, three had proteinuria, and three had peripheral vascular disease. The histories of diabetic and non-diabetic patients were similar but fewer diabetic patients were current smokers. The frequency of arrhythmias was similar in the two groups.There was a trend to more haemodynamic complications but the numbers are too small for valid statistical analysis. Because of the exclusion criteria the death rate was low in both groups.
Whatever the method of assessment used diabetic patients did not have larger infarcts than non-diabetic patients (Table 3 ). The 95% confidence limits of the sum of creatine kinase MB release are such that infarct size in diabetic patients might have exceeded by up to 33 U/I that in non-diabetics, but the chance that a larger excess could have been missed is less than 2-5%. If the non-diabetic sample is assumed to be identical with the non-diabetic population, the maximum excess diabetic infarct size that could be missed by chance (at the 2-5% level) would be 6% of the infarct size in concentrations15 that would be expected in the diabetic patient after infarction. We have examined the possibility of a systematic increase in infarct size in diabetics by using three complementary sets of observations-a retrospective 16 year study of all diabetics with a relatively non-specific enzyme method of estimating infarct size, a matched series in which aspartate aminotransferase was measured, and a study which excluded some of the more seriously ill patients but which used a more specific and precise enzyme technique (creatine kinase MB) reinforced by analysis of the 12 lead electrocardiogram. In none of these three sets of patients did the diabetic patients have larger infarcts than the non-diabetic ones. This accords with the results of Jaffe et al who showed that although diabetic patients have increased rates of cardiac failure after myocardial infarction, infarct size in these patients is less than that of the non-diabetic patients. 28 Thus, although in theory there are mechanisms by which the diabetic might be at risk of more extensive infarction, these do not appear to be important in practice. We have also found that careful metabolic control after infarction has little effect on mortality.29 Therefore, the unknown cause of the excess death rate may well operate before the fatal infarction occurs. The most likely explanation appears to be previous left ventricular disease, possibly vascular in origin or possibly related to some other aspect of diabetes. Attempts to improve survival among diabetic patients should be instituted before the onset of infarction.
